A5103049073- Inflammatory Bowel Disease
- Atrial Fibrillation Management and Outcomes
- Bone health and treatments
- Esophageal and GI Pathology
- Global Health Workforce Issues
- Immunodeficiency and Autoimmune Disorders
- Pancreatic and Hepatic Oncology Research
- Diversity and Career in Medicine
- Cardiac Arrhythmias and Treatments
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Psoriasis: Treatment and Pathogenesis
- Microscopic Colitis
- Healthcare Policy and Management
- Autoimmune and Inflammatory Disorders
- Bone and Joint Diseases
- Eosinophilic Esophagitis
- Neuroendocrine Tumor Research Advances
- Sarcoidosis and Beryllium Toxicity Research
- Cardiac Imaging and Diagnostics
- Vitamin D Research Studies
- Lung Cancer Treatments and Mutations
- Cardiac electrophysiology and arrhythmias
- Gallbladder and Bile Duct Disorders
- Dental Education, Practice, Research
Bradford Royal Infirmary
2023
Janssen (United States)
2021-2022
Bayer (Germany)
2019
KLE Society Hospital
2018
Sir Ganga Ram Hospital
2018
Universidad de Montevideo
2018
Montefiore Medical Center
2016
Mount Sinai Medical Center
2012
Universitat de Barcelona
1994
Guselkumab, a selective p19 interleukin-23 antagonist, is approved for the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated efficacy safety guselkumab in patients with moderately to severely active Crohn's disease inadequate response or intolerance conventional biologic therapy.GALAXI-1, phase 2, double-blind, placebo-controlled study, randomized 1:1:1:1:1 intravenous 200 mg, 600 1200 mg at weeks 0, 4, 8; ustekinumab approximately 6 mg/kg week 0 90 subcutaneously...
Summary A 77-year-old female patient with a history of treated breast cancer and recently diagnosed laryngeal presented severe hypercalcaemia associated suppressed parathyroid hormone (PTH) levels. Her initial investigations included 25-hydroxy vitamin D levels, short synacthen test, bone scan, myeloma screen thyroid function tests which were within normality. computerised tomography (CT) scan showed some right lung apical fibrotic changes. PTH-related peptide (PTHrP) was normal sarcoidosis...
Abstract Background Guselkumab (GUS), an IL-23 antagonist, is being investigated for the treatment of IBD. GALAXI 1 a ph2, double-blind, PBO-controlled study in pts with moderately to severely active CD inadequate response or intolerance conventional therapies (corticosteroid, immunosuppressant) and/or biologics (TNF vedolizumab). Here we report early clinical outcome measures during induction GUS vs PBO. Methods Pts moderate severe (CDAI score 220–450) were randomized 1:1:1:1:1 200, 600...
The preservation of the neurovascular supply to antrum, pylorus and first part duodenum (APD) via right gastric (RG) supraduodenal artery (SPD) is essential for success pylorus-preserving pancreaticoduodenectomy (PPPD) prevent delayed emptying (DGE). We analyzed 41 patients with malignant neoplasm 25 chronic pancreatitis. Preservation blood APD was not possible in 19 (46.3%) group DGE occurred 84.2% patients. Furthermore 4 had intra-abdominal sepsis all RG and/or SPD arteries were preserved...
Introduction: GALAXI 1 is a ph 2, double-blind, PBO-controlled study of guselkumab (GUS), an IL-23 antagonist, for the treatment pts with moderately to severely active CD who had inadequate response or intolerance conventional therapies (corticosteroid, immunosuppressant) and/or biologics (TNF vedolizumab). PRO-2 symptom remission measurement efficacy based on mean daily patient reported symptoms abdominal pain (none, mild, moderate and severe) number liquid very soft stools (stool...
Introduction: GALAXI 1 is a phase 2, double-blind, placebo-controlled study of guselkumab (GUS), an IL-23 antagonist, for the treatment patients (pts) with moderately to severely active Crohn’s disease (CD) who had inadequate response or intolerance conventional therapies (corticosteroid, immunosuppressant) and/or biologics (TNF vedolizumab). Patient-reported outcomes from Inflammatory Bowel Disease Questionnaire (IBDQ) through Week (Wk) 12 following GUS induction are reported here interim...